Preferred Label : Programmed cell death ligand 1 by clone SP142:PrThr:Pt:Tiss:Ord:Immune stain;
LOINC status : ACTIVE;
LOINC display name : PD-L1 by clone SP142 Immune stain Ql (Tiss);
LOINC long common name : PD-L1 by clone SP142 [Presence] in Tissue by Immune stain;
LOINC short name : PD-L1 by SP142 Tiss Ql ImStn;
LOINC description : This term should be used to report the degree of PD-L1 (CD274) protein expression
in tumor cells as determined by immune staining with anti-PD-L1 clone SP142. Patients
with certain cancers, such as non small cell lung cancer (NSCLC) or urothelial carcinoma,
whose tumors are positive for PD-L1 by SP142, may be eligible for anti-programmed
death 1 (PD-1) receptor antibody therapy, which effectively prevents the binding of
PD-L1 to PD-1. The percentage of viable tumor cells that show partial or complete
PD-L1 membrane staining is reported using [LOINC: 83053-9]. If at least 50% of tumor
cells or at least 10% of inflammatory cells stain positive with SP142, the tumor is
considered to have high PD-L1 expression, and if 1 to 50% of tumor cells and 1 to
10% of inflammatory cells stain positive, the tumor has low expression. If 1% of
both tumor and inflammatory cells stain positive, the tumor is considered to have
no PD-L1 expression. This term was created for, but is not limited in use to, the
Ventana PD-L1 (SP142) assay, which, as of November 2016, is FDA-approved as a companion
diagnostic to assess whether patients with certain cancers are eligible for atezolizumab
therapy.;
Origin ID : 83057-0;
UMLS CUI : C4298261;
Has component
- Has method
- Has property
- Has scale
- Has system
- Has time aspect
- Semantic type(s)
